JP2018512397A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018512397A5 JP2018512397A5 JP2017547001A JP2017547001A JP2018512397A5 JP 2018512397 A5 JP2018512397 A5 JP 2018512397A5 JP 2017547001 A JP2017547001 A JP 2017547001A JP 2017547001 A JP2017547001 A JP 2017547001A JP 2018512397 A5 JP2018512397 A5 JP 2018512397A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- subject
- agonist
- administering
- chemotherapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 65
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 42
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 42
- 239000000556 agonist Substances 0.000 claims description 38
- 238000002512 chemotherapy Methods 0.000 claims description 34
- 206010028980 Neoplasm Diseases 0.000 claims description 27
- 230000005855 radiation Effects 0.000 claims description 26
- 208000029742 colonic neoplasm Diseases 0.000 claims description 12
- 230000004069 differentiation Effects 0.000 claims description 12
- 210000002540 macrophage Anatomy 0.000 claims description 12
- 206010009944 Colon cancer Diseases 0.000 claims description 10
- 238000001959 radiotherapy Methods 0.000 claims description 10
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 6
- 230000002708 enhancing effect Effects 0.000 claims description 6
- 238000005259 measurement Methods 0.000 claims description 5
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 108020001507 fusion proteins Proteins 0.000 claims description 4
- 102000037865 fusion proteins Human genes 0.000 claims description 4
- 210000002865 immune cell Anatomy 0.000 claims description 4
- 230000002163 immunogen Effects 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 230000004083 survival effect Effects 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 229950007217 tremelimumab Drugs 0.000 claims description 4
- 230000004614 tumor growth Effects 0.000 claims description 3
- 102000004452 Arginase Human genes 0.000 claims description 2
- 108700024123 Arginases Proteins 0.000 claims description 2
- 238000009175 antibody therapy Methods 0.000 claims description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 2
- 229960005277 gemcitabine Drugs 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562131562P | 2015-03-11 | 2015-03-11 | |
| US62/131,562 | 2015-03-11 | ||
| PCT/US2016/021486 WO2016145030A1 (en) | 2015-03-11 | 2016-03-09 | Compositions and methods for enhancing the efficacy of cancer therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018512397A JP2018512397A (ja) | 2018-05-17 |
| JP2018512397A5 true JP2018512397A5 (enExample) | 2019-04-18 |
Family
ID=56880519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017547001A Pending JP2018512397A (ja) | 2015-03-11 | 2016-03-09 | 癌治療の有効性を高めるための組成物及び方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20180044428A1 (enExample) |
| EP (1) | EP3268387A4 (enExample) |
| JP (1) | JP2018512397A (enExample) |
| KR (1) | KR20180002597A (enExample) |
| CN (1) | CN107531773A (enExample) |
| AU (1) | AU2016229810A1 (enExample) |
| CA (1) | CA2978318A1 (enExample) |
| HK (1) | HK1247630A1 (enExample) |
| IL (1) | IL254103A0 (enExample) |
| RU (1) | RU2017134104A (enExample) |
| SG (1) | SG11201706958SA (enExample) |
| WO (1) | WO2016145030A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY189692A (en) | 2015-05-07 | 2022-02-26 | Memorial Sloan Kettering Cancer Center | Anti-ox40 antibodies and methods of use thereof |
| US20160347848A1 (en) * | 2015-05-28 | 2016-12-01 | Medimmune Limited | Therapeutic combinations and methods for treating neoplasia |
| WO2017021913A1 (en) * | 2015-08-04 | 2017-02-09 | Glaxosmithkline Intellectual Property Development Limited | Combination treatments and uses and methods thereof |
| IL299072A (en) | 2015-12-02 | 2023-02-01 | Memorial Sloan Kettering Cancer Center | Antibodies and methods of use thereof |
| CA3041340A1 (en) | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof |
| EP3582855A1 (en) * | 2017-02-15 | 2019-12-25 | GlaxoSmithKline Intellectual Property Development Limited | Combination treatment for cancer |
| CA3095134A1 (en) | 2018-03-28 | 2019-10-03 | Board Of Regents, The University Of Texas System | Identification of epigenetic alterations in dna isolated from exosomes |
| WO2020118216A1 (en) * | 2018-12-08 | 2020-06-11 | Board Of Regents, The University Of Texas System | Identification and targeting of tumor promoting carcinoma associated fibroblasts for diagnosis and treatment of cancer and other diseases |
| CN112007149A (zh) * | 2019-05-29 | 2020-12-01 | 思格(苏州)生物科技有限公司 | 一种新型复合免疫佐剂及其应用 |
| WO2021062332A1 (en) * | 2019-09-27 | 2021-04-01 | Icahn School Of Medicine At Mount Sinai | Combination of inhibitors of il4 signaling and immune checkpoints for treating cancer |
| WO2021098851A1 (en) * | 2019-11-20 | 2021-05-27 | Eucure (Beijing) Biopharma Co., Ltd | Anti-ctla4/ox40 bispecific antibodies and uses thereof |
| US20230002499A1 (en) * | 2019-11-21 | 2023-01-05 | Beigene (Beijing) Co., Ltd. | Methods of cancer treatment with anti-ox40 antibody in combination with chemotherapeutic agents |
| CN113045655A (zh) * | 2019-12-27 | 2021-06-29 | 高诚生物医药(香港)有限公司 | 抗ox40抗体及其用途 |
| JP2023525140A (ja) * | 2020-05-13 | 2023-06-14 | アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） | Ｏｘ４０活性化特性を有する組換えタンパク質 |
| EP4448111A1 (en) * | 2021-12-15 | 2024-10-23 | Board of Regents, The University of Texas System | Methods and compositions for altering a tumor microbiome |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007107349A1 (en) * | 2006-03-22 | 2007-09-27 | Apogenix Gmbh | Antibody specific for human il-4 for the treament of cancer |
| EP2007423A2 (en) * | 2006-04-05 | 2008-12-31 | Pfizer Products Incorporated | Ctla4 antibody combination therapy |
| MX2009009194A (es) * | 2007-02-27 | 2009-10-08 | Genentech Inc | Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes. |
| WO2010014784A2 (en) * | 2008-08-01 | 2010-02-04 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
| EP2769737B1 (en) * | 2009-07-20 | 2017-04-05 | Bristol-Myers Squibb Company | Combination of an anti-CTLA4 antibody with etoposide for the synergistic treatment of proliferative diseases |
| WO2011146382A1 (en) * | 2010-05-17 | 2011-11-24 | Bristol-Myers Squibb Company | Improved immunotherapeutic dosing regimens and combinations thereof |
| GB201116092D0 (en) * | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
| WO2013114367A2 (en) * | 2012-02-01 | 2013-08-08 | Compugen Ltd. | C10rf32 antibodies, and uses thereof for treatment of cancer |
| WO2017134292A1 (en) * | 2016-02-04 | 2017-08-10 | Glenmark Pharmaceuticals S.A. | Anti-ox40 antagonistic antibodies for the treatment of atopic dermatitis |
-
2016
- 2016-03-09 WO PCT/US2016/021486 patent/WO2016145030A1/en not_active Ceased
- 2016-03-09 CA CA2978318A patent/CA2978318A1/en not_active Abandoned
- 2016-03-09 EP EP16762392.5A patent/EP3268387A4/en not_active Withdrawn
- 2016-03-09 AU AU2016229810A patent/AU2016229810A1/en not_active Abandoned
- 2016-03-09 SG SG11201706958SA patent/SG11201706958SA/en unknown
- 2016-03-09 HK HK18107203.8A patent/HK1247630A1/zh unknown
- 2016-03-09 JP JP2017547001A patent/JP2018512397A/ja active Pending
- 2016-03-09 US US15/556,864 patent/US20180044428A1/en not_active Abandoned
- 2016-03-09 CN CN201680014559.7A patent/CN107531773A/zh active Pending
- 2016-03-09 KR KR1020177025629A patent/KR20180002597A/ko not_active Withdrawn
- 2016-03-09 RU RU2017134104A patent/RU2017134104A/ru not_active Application Discontinuation
-
2017
- 2017-08-22 IL IL254103A patent/IL254103A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018512397A5 (enExample) | ||
| JP6987945B2 (ja) | ヒトメソテリンキメラ抗原受容体およびその使用 | |
| JP2018521008A5 (enExample) | ||
| Neoptolemos et al. | Therapeutic developments in pancreatic cancer: current and future perspectives | |
| Kim et al. | A phase II study of avelumab monotherapy in patients with mismatch repair-deficient/microsatellite instability-high or POLE-mutated metastatic or unresectable colorectal cancer | |
| JP2019521641A5 (enExample) | ||
| Cai et al. | Apatinib enhanced anti-PD-1 therapy for colon cancer in mice via promoting PD-L1 expression | |
| Khan et al. | Listeria monocytogenes: a model pathogen to study antigen-specific memory CD8 T cell responses | |
| JP2022543555A (ja) | ｍｉＲＮＡ－１９３ａに関する新たな処置 | |
| JP2020520912A5 (enExample) | ||
| TWI895295B (zh) | 偵測編碼新生抗原之融合基因之方法 | |
| Tarhini et al. | Neoadjuvant immunotherapy of locoregionally advanced solid tumors | |
| JP2023508947A (ja) | 循環腫瘍ｄｎａの分析を介した分子疾患評価のための方法およびシステム | |
| CN115427069A (zh) | 减小遗传抽样中的统计偏差 | |
| EP4084810A1 (en) | Immunotherapeutic treatment of cancer | |
| Pietrantonio et al. | Systemic treatment of patients with gastrointestinal cancers during the COVID-19 outbreak: COVID-19-adapted recommendations of the National Cancer Institute of Milan | |
| Kim et al. | Strategies to overcome hurdles in cancer immunotherapy | |
| Alsaafeen et al. | Combinational therapeutic strategies to overcome resistance to immune checkpoint inhibitors | |
| CN118317778A (zh) | 工程化nk细胞及其用途 | |
| US20220265820A1 (en) | Tumor immunotherapy using sindbis viral vectors and agonist monoclonal antibodies | |
| Iveson et al. | 6504 ORAL safety and efficacy of epirubicin, cisplatin, and capecitabine (ECX) plus rilotumumab (R) as first-line treatment for unresectable locally advanced (LA) or metastatic (M) gastric or esophagogastric junction (EGJ) adenocarcinoma | |
| Xia et al. | Immunotherapy resistance in malignant pleural mesothelioma: Mechanistic foundations, clinical evidence, and precision therapeutic strategies | |
| WO2022096896A1 (en) | Mycobacterial immunotherapy for treating cancer | |
| Brito | CANCER IMMUNOTHERAPY | |
| US20230405059A1 (en) | A mycobacterium for use in cancer therapy |